Summary
Ultragenyx Pharmaceutical Inc (Ultragenyx) is a biotechnology company that develops life-enhancing therapeutics for rare and ultra-rare genetic diseases. The company’s products include KRN23, rhPPCA, rhGUS, UX007 and Aceneuramic acid. Its Aceneuramic acid is developed for multiple rare genetic disorders. Ultragenyx develops recombinant fully human monoclonal IgG1 antibody, KRN23 to treat bone disease X-Linked Hypophosphatemia and tumor-induced osteomalacia. The company also develops investigational enzyme replacement therapies, recombinant human beta-glucuronidase for the development for Mucopolysaccharidosis 7 and rhPPCA for treatment of galactosialidosis. It partners with academic institutes and companies. Ultragenyx is headquartered in Novato, California, the US.
Ultragenyx Pharmaceutical Inc (RARE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Ultragenyx Pharma Raises US$75 Million In Series B Financing 11
Ultragenyx Pharma Raises US$15.1 Million In Venture Financing 14
Ultragenyx Pharma Secures US$45 Million In Series A Financing 15
Partnerships 17
Takeda Pharma to Enter into Co-Development Agreement with Ultragenyx Pharma 17
Ultragenyx Pharma Enters into Research Agreement with Saint Louis University 18
Licensing Agreements 19
Ultragenyx Pharma Enters into Licensing Agreement with Arcturus Therapeutics 19
Ultragenyx Pharma Enters into Licensing Agreement with UniQuest for Triheptanoin 20
Ultragenyx Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For KRN23 21
Ultragenyx Pharma Expands Licensing Agreement With Baylor Research Institute For Triheptanoin 23
Ultragenyx Pharma Enters Into Licensing Agreement With Baylor Research Institute For Triheptanoin 25
Ultragenyx Pharma Enters Into Licensing Agreement With Saint Louis University 27
NobelPharma Enters Into Licensing Agreement With Ultragenyx Pharma For UX-001 28
Equity Offering 29
Ultragenyx Pharma to Raise up to USD65 Million in Private Placement of Shares 29
Ultragenyx Pharma Completes Public Offering of Shares for USD303.6 Million 31
Ultragenyx Pharma Raises USD162 Million in Public Offering of Shares 33
Ultragenyx Pharma Raises USD76.7 Million in Public Offering of Shares 35
Ultragenyx Pharma Completes IPO For US$139 Million 37
Ultragenyx Pharmaceutical Inc - Key Competitors 39
Key Employees 40
Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Ultragenyx Pharmaceutical Inc, Deals By Therapy Area, 2010 to YTD 2016 8
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Ultragenyx Pharma Raises US$75 Million In Series B Financing 11
Ultragenyx Pharma Raises US$15.1 Million In Venture Financing 14
Ultragenyx Pharma Secures US$45 Million In Series A Financing 15
Takeda Pharma to Enter into Co-Development Agreement with Ultragenyx Pharma 17
Ultragenyx Pharma Enters into Research Agreement with Saint Louis University 18
Ultragenyx Pharma Enters into Licensing Agreement with Arcturus Therapeutics 19
Ultragenyx Pharma Enters into Licensing Agreement with UniQuest for Triheptanoin 20
Ultragenyx Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For KRN23 21
Ultragenyx Pharma Expands Licensing Agreement With Baylor Research Institute For Triheptanoin 23
Ultragenyx Pharma Enters Into Licensing Agreement With Baylor Research Institute For Triheptanoin 25
Ultragenyx Pharma Enters Into Licensing Agreement With Saint Louis University 27
NobelPharma Enters Into Licensing Agreement With Ultragenyx Pharma For UX-001 28
Ultragenyx Pharma to Raise up to USD65 Million in Private Placement of Shares 29
Ultragenyx Pharma Completes Public Offering of Shares for USD303.6 Million 31
Ultragenyx Pharma Raises USD162 Million in Public Offering of Shares 33
Ultragenyx Pharma Raises USD76.7 Million in Public Offering of Shares 35
Ultragenyx Pharma Completes IPO For US$139 Million 37
Ultragenyx Pharmaceutical Inc, Key Competitors 39
Ultragenyx Pharmaceutical Inc, Key Employees 40
List of Figures
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
